Plus, news from Vicore, Elevate Bio, Monte Rosa Therapeutics and Angitia:
Intas, Henlius ink another deal:
Intas
said
Friday it plans to pay €42 million upfront to license Shanghai Henlius Biotech’s anti-PD-1 monoclonal antibody in Europe and India for specific indications. The terms also include up to €43 million in regulatory milestones and up to €100 million in sales milestones, plus royalties. The companies expect serplulimab to gain approval in small cell lung cancer in Europe in the first half of next year. The companies are already engaged in several agreements, including one set up in 2018 between Henlius and Accord Healthcare, an Intas subsidiary. —
Jaimy Lee